Lonza adds HPAPI manufacturing capabilities to its Nansha, China site

The development and cGMP manufacturing laboratories will provide additional early-phase HPAPI manufacturing capabilities

This milestone is part of the Swiss company's recent investment to expand the mid-scale manufacturing capacity at the site.

Specifically, the expansion has increased the laboratory footprint to 250 m2 and extended the capabilities and capacity of development laboratories and kilogram-scale cGMP manufacturing laboratories for clinical supply of HPAPIs, especially those supporting oncology.

The new laboratories also form part of Lonza's strategy to increase its global HPAPI manufacturing network to meet growing customer demand, as HPAPIs currently form a significant part of Lonza’s small molecule development pipeline.

According to the company's Jan Vertommen, Executive Director, Commercial Development, Small Molecules, more than 1000 HPAPIs are in development across multiple indications.

The decision to expand at this site means the company has access to local suppliers of raw materials which, in turn, will positively affect the speed of manufacturing.

The company also reports that it has already secured its first European and US-headquartered customers who have signed HPAPI programmes for the new laboratories in Nansha, which will become operational this month.